Misonix (NASDAQ:MSON) issued its quarterly earnings results on Thursday. The medical equipment provider reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34, Fidelity Earnings reports. The company had revenue of $11.15 million for the quarter. Misonix had a negative net margin of 19.01% and a negative return on equity of 25.99%.
MSON stock traded up $2.87 during mid-day trading on Friday, reaching $19.62. The company had a trading volume of 103,600 shares, compared to its average volume of 43,956. Misonix has a 12 month low of $13.87 and a 12 month high of $27.54. The firm has a 50 day moving average of $18.09 and a 200 day moving average of $20.76.
Several equities analysts recently commented on MSON shares. Canaccord Genuity reiterated a “buy” rating and set a $30.00 price target (up from $24.00) on shares of Misonix in a report on Thursday, August 15th. BTIG Research restated a “buy” rating and issued a $27.00 target price on shares of Misonix in a research note on Thursday, August 15th. Finally, ValuEngine downgraded shares of Misonix from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Misonix currently has a consensus rating of “Buy” and a consensus price target of $28.50.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.